Scientists at Uppsala University and the Sahlgrenska Academy, University of Gothenburg say they have developed a blood test that may provide a more precise diagnostic for suspected ovarian cancer that would eliminate the need for exploratory surgery. This could lead … Read more
By Mark L. Fuerst… Read more
By Dave Levitan
An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more
By Dave Levitan
Maintenance therapy with the PARP inhibitor rucaparib offered improved post-progression outcomes in a phase III trial of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in a complete or partial response to … Read more
What is a CA125 blood test?
CA125 is a protein that both men and women have in their blood. The normal level of this is 35 units per millilitre (U/mL), or lower.
A CA125 blood test is used to check … Read more
Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more
By Leah Lawrence
Single-agent carboplatin conferred significantly worse survival outcomes in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer compared with weekly or every 3 weeks carboplatin/paclitaxel, according to results of the EWOC-1 trial (abstract 5508), which … Read more
University of North Carolina Lineberger Comprehensive Cancer Center researchers have uncovered the mechanism that explains how an investigational cancer therapeutic might be working—a finding that they believe could be important for the design of potential new therapies.
In the journal … Read more
By Ian Ingram
Benefit seen across all subgroups for patients with platinum-sensitive disease.
Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more
Helpful advice from experts and a mom who’s been there twice.
When you’re diagnosed with cancer, processing it is hard, and figuring out how to tell your kids about it just adds to the stress and … Read more
Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects.
Luckily, doctors have a variety of ways to relieve or prevent these discomforts.… Read more
By Kelly Irvin
A second ovarian cancer recurrence in three years prompted this review of lessons learned. If I could go back three and a half years and give advice to my newly diagnosed self, what would I say?
This … Read more
By Sarah Elizabeth Richards
Photo: Liz Laats with husband Andy Laats and their three children. She died three years ago of ovarian cancer. The San Diego resident had suffered through 88 rounds of chemotherapy during 10 treatment regimens over six … Read more
In what they claim is the first large-scale systematic analysis of thousands of gene fusions in human cancers, scientists have identified a gene fusion that could represent a novel drug target for multiple cancers. Through their studies, the largely U.K.-based … Read more
According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more